This Viewpoint discusses how to fill policy gaps surrounding the use of psychedelics to treat mental health and substance use conditions, should they be approved by the US Food and Drug Administration.
This Viewpoint discusses the need to better understand potential risks associated with psychedelic and 3,4-methylenedioxymethamphetamine (MDMA) use to ensure safe and ethical practice and identifies 4 key research goals.
Despite growing interest in psychedelics, there is a lack of routine population-based surveillance of psychedelic microdosing (taking "subperceptual" doses of psychedelics, approximately one-twentieth to one-fifth of a full dose, over prolonged periods). Analyzing Google search queries can provide insights into public interest and help address this gap. To analyze trends in public interest in...
In 2020, Oregon became the first state in the US to decriminalize use of many illicit substances, including mushrooms containing psilocybin, and allow adults aged 21 years and older to take psilocybin under supervision in state-licensed service centers.Numerous states and municipalities have since proposed similar policies, 1 a process catalyzed by excitement about positive clinical trials of...